Eli Lilly announced that the Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) significantly improved event-free survival by reducing the risk of recurrence or death by 83% compared to placebo in early-stage RET fusion-positive non-small cell lung cancer patients. This is the first proven targeted adjuvant therapy for this patient group, highlighting the need for comprehensive biomarker testing at diagnosis. The results, to be published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting, may change clinical practice by establishing Retevmo as a new standard of care after surgery or radiation.
Eli Lilly has solidified its dominance in the global obesity drug market, maintaining a 60-61% market share in the US despite rising competition and pricing challenges. The company continues to grow through increasing prescriptions and expanding glob...
The Vanguard Growth ETF (VUG) charges a very low fee of 0.03%, costing about $3 annually on a $10,000 investment. However, the real risk lies in its heavy concentration, with over 65% of the fund invested in just ten large-cap stocks like NVIDIA, App...
Eli Lilly shows strong performance with 48% revenue growth driven by GLP-1 drugs Mounjaro and Zepbound, raising 2026 guidance significantly. Novo Nordisk struggles with pricing cuts and pipeline setbacks, keeping its stock range-bound despite solid s...
Eli Lilly became the first pharmaceutical company valued over $1 trillion, driven by strong revenue growth and promising drugs like retatrutide and orforglipron. The company reported a 47.67% revenue increase in Q2 and raised its 2026 revenue guidanc...
Aktis Oncology, a clinical-stage radiopharmaceutical company, closed at $25.00 on August 18, 2026, with a market cap of $1.4 billion and $517.3 million in cash, supporting operations into 2029. Its lead candidate targets Nectin-4 with trial data expe...
